Achieve total and faster wound healing with AUP-16, a topical cell therapy that accelerates healing of diabetic foot ulcers and other chronic, non-healing wounds.
Chronic and non-healing wound treatment is
Many available products can treat symptoms or target limited steps in the wound healing pathway: traditional or moist wound dressings, negative pressure wound therapy, cell and tissue based products, skin substitutes, growth factors.... Aurealis Therapeutics’ four-in-one topical treatment, AUP-16, accelerates healing by targeting multiple wound healing pathways and promoting tissue regeneration. Our unique technology overcomes the limitations of combining current treatments or combining existing therapeutic protein treatments, replacing them with a single therapeutic agent.
One medicine has the benefits of four therapeutics
AUP-16 is a safe and effective recombinant live biotherapeutic product that features a patented active bacterial vector containing three therapeutic proteins (FGF2, IL4, and CSF1), produced continuously at the site of the wound, providing a combination biologic treatment in one product.
This novel therapeutic is backed by pre-clinical and clinical results in wide-ranging applications like diabetic foot ulcers, other non-healing wounds, and inflammatory diseases. AUP-16 is made from live, food-grade bacteria and has the power to accelerate and provide complete wound healing, making future amputations unnecessary.
This remarkable advancement is ideal for patients who only achieve partial response to wound care dressings and treatment of symptoms. As opposed to the existing standard of care, AUP-16 promotes tissue regeneration in the wound to activate healing from within.
Highlights of AUP-16
cell therapy stimulates
at the site of injury
makes it easy to
For Investors and Strategic Partners
Basel Switzerland, Kuopio Finland, and Shenzhen China – January 28th, 2021. Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis … Aurealis Therapeutics and Xbiome...Read
Basel Switzerland, Kuopio Finland – May 27th, 2021. Aurealis Therapeutics, a biopharmaceutical company developing its groundbreaking four-in-one technology -based product AUP-16, announced today that it has successfully completed the low therapeutic dose cohort in the diabetic foot ulcer (DFU) patient trial and has already enrolled and dosed the first patients in the medium therapeutic dose … Aurealis Therapeutics Diabetic Foot...Read
Basel Switzerland, Kuopio Finland – December 15th, 2020. Haritha Samaranayake, MD, PhD, Medical Director of Aurealis Therapeutics will give a talk about development of AUP16, the company´s lead product for non-healing wounds such as diabetic foot ulcer. The presentation is titled “Development of a Live Biotherapeutic to treat diabetic foot ulcer“ and is scheduled for … Aurealis Therapeutics Novel Chronic...Read